Hepatocellular carcinoma and lifestyles

Saran, Uttara; Humar, Bostjan; Kolly, Philippe; Dufour, Jean–François

doi:10.1016/j.jhep.2015.08.028

Cited by 99 publications

(86 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analyses of adjusted estimates were emphasized on studies controlling for HBV/HCV infection, cirrhosis, obesity, behavioral factors, use of statins, and time-related bias, given their modifying effects on metformin's activity on DM and liver cancer risk. [18–20] Publication bias was detected for overall analysis using Begg test and Egger test (publication bias considered present if P ≤ .1). [21,22] All the statistical analyses were 2-sided and performed using Stata version 12.0 (StataCorp, College Station, TX).…”

Section: Methodsmentioning

confidence: 99%

Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients

Zheng

Xiao

et al. 2017

Medicine

View full text Add to dashboard Cite

Metformin has garnered more interest as a chemo-preventive agent given the increased liver cancer risk in diabetic patients. This work was undertaken to better understand the effect of metformin use on liver cancer risk in diabetic patients.A comprehensive literature search was performed in PubMed, Embase, BIOSIS Previews, Web of Science, and Cochrane Library through July 30, 2016. Meta-analyses were performed using Stata version 12.0, with odds ratio (ORs) and 95% confidence intervals (CIs) as effect measures.Twenty-three studies were included. Meta-analysis of 19 studies involving 550,882 diabetic subjects suggested that metformin use reduced the ratio of liver cancer by 48% (OR = 0.52; 95% CI, 0.40–0.68) compared with nonusers. The protective effect was validated in all the exploratory subgroup analyses, except that pooled result of post hoc analyses of 2 randomized controlled trials found no significant difference between subjects with metformin and those without, with OR being 0.84 (95% CI, 0.10–6.83). After adjusting for hepatitis B/C virus infection, cirrhosis, obesity, behavioral factors, and time-related bias, the association was stable, pooled OR ranged from 0.42 to 0.75.A protective effect for liver cancer was found in diabetic metformin users. However, more randomized clinical evidence is still needed to verify the results.

show abstract

Section: Methodsmentioning

confidence: 99%

Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients

Zheng

Xiao

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…A testsúlycsökke-néshez vezető életmód-változtatásban különösen fontos a beteg adherenciája, a visszaesés megakadályozása, ebben kulcsszerepet kaphat a kognitív viselkedésterápia [54]. Saran és mtsai szerint az életmódváltozás, különös tekintettel a fizikai aktivitásra, jelentős tényező lehet a NAFLD és az obesitas okozta HCC megelőzésében [55].…”

Section: Fizikai Aktivitásunclassified

Nem alkoholos zsírmáj és hepatocellularis carcinoma – 2016

Pár

2016

Orvosi Hetilap

View full text Add to dashboard Cite

Az utolsó évtizedben a fejlett országokban a nem alkoholos zsírmáj lett a leggyakrabban diagnosztizált krónikus májbetegség. Ugyanakkor e kórképnek, de különösen súlyosabb formájának, a nem alkoholos steatohepatitisnek a szerepe bizonyított a hepatocellularis carcinoma gyakoriságának drámai megnövekedésében. A fő kockázati tényezők a genetikai prediszpozíció mellett az obesitas és a diabetes, valamint a kórfolyamatban gyakran fibrosishoz vezető alacsony fokú krónikus gyulladás. A patogenezisben a szabad zsírsavak és citokinek, a lipotoxicitás, az inzulinrezisztencia, a mikro-RNS-diszreguláció és a bél-baktériumflóra megváltozása kulcsfontosságú. A nem alkoholos zsírmáj kezelése -obesitasban a testsúlycsökkentés és fizikai aktivitás, diabetesben a metformin, dyslipidaemiában a statinok és új lehetőségként az obetikólsav -e betegség következményeként kialakuló hepatocellularis carcinoma prevenció-ját is szolgálhatja. Orv. Hetil., 2016, 157(25), 987-994.Kulcsszavak: nem alkoholos zsírmáj, nem alkoholos steatohepatitis, hepatocellularis carcinoma, genetika, citokinek, inzulinrezisztencia, mikro-RNS, bél-baktériumflóra, diagnózis, szűrés, terápia, obetikólsav, daganatprevenció Non-alcoholic fatty liver disease and hepatocellular carcinoma -2016In the past decade non-alcoholic liver disease became the most frequently diagnosed liver disease in developed countries. At the same time, the dramatic rise in the incidence of hepatocellular carcinoma is attributed to this common metabolic disorder, and mainly to its severe form, non-alcoholic steatohepatitis. The risk factors of these associated diseases are genetic predisposition, obesity and diabetes as well as chronic low grade necro-infammation, which often leads to liver fibrosis. Free fatty acids, cytokines, lipotoxicity, insulin resistance, microRNS dysregulation and alteration in intestinal microbiota play a pivotal role in the pathogenesis. Treatment of non-alcoholic fatty liver disease -weight reduction and physical exercise in obesity, metformin in diabetes, statins in dyslipidemia and, as a new option, obeticholic acid -may diminish the risk of the hepatocellular carcinoma related to this metabolic disease.Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatocellular carcinoma, genetics, cytokines, insulin resistance, microRNA, intestinal microbiota, diagnosis, surveillance, treatment, obeticholic acid, cancer prevention Rövidítések ALP (GPT) = alanin-aminotranszferáz; AMPK = adenozinmonofoszfát-aktivált proteinkináz; BMI = testtömegindex; CDA = chenodezoxikólsav; DNS = dezoxiribonukleinsav; FFA = szabad zsírsav; FGF = fibroblastnövekedési faktor; HBV = hepatitis B-vírus; HCC = hepatocellularis carcinoma; HCV = hepatitis C-vírus; HR = hazard ratio; HSC = hepaticus csillag-(stellatum) sejt; IL = interleukin; IR = inzulinrezisztencia; IRS-1 = inzulinreceptor-szubsztrát-1; KS = Kupffer-sejt; LSP = lipopoliszacharida; MAPK = mitogénaktivált proteinkináz; miR = mikro-RNS; MMP = metalloproteináz; NAFLD = nem alkoholos zsírmáj; NASH = nem al...

show abstract

“…In the last decade, a strong association between lifestyle and hepatocellular carcinoma has become evident. Abundance of energy-rich food and sedentary lifestyles have caused metabolic conditions such as obesity and diabetes mellitus to become global epidemics (Saran et al, 2016). Cytokines are humoral immunomodulatory proteins or glycoproteins which control or modulate the activities of target cells, generally those within the haematopoietic system.…”

Section: Genetic Unit Of Pediatric 3 Internal Medicine Departments mentioning

confidence: 99%

Single Nucleotide Polymorphism in Cytokines and Risk of Hepatocellular Carcinoma in Egyptian Patients

Abdel-Azyem

Abdel-Aziz

Elbaz³

et al. 2016

Egyptian Journal of Genetics and Cytology

View full text Add to dashboard Cite

Hepatocellular carcinoma and lifestyles

Cited by 99 publications

References 110 publications

Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients

Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients

Nem alkoholos zsírmáj és hepatocellularis carcinoma – 2016

Single Nucleotide Polymorphism in Cytokines and Risk of Hepatocellular Carcinoma in Egyptian Patients

Contact Info

Product

Resources

About